Results 31 to 40 of about 8,451 (198)

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils : The REDES Study [PDF]

, 2021
The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits the generalizability of results.
Bañas-Conejero, David, Carrillo Díaz, Teresa, Blanco-Aparicio, Marina, Sánchez Herrero, M. Guadalupe, Universitat Autònoma de Barcelona. Departament de Medicina, Domingo, Christian, Martínez Moragón, Eva   +6 more
core   +1 more source

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma [PDF]

Farmacia Hospitalaria, 2019
Objective: Mepolizumab is indicated as an additional treatment of severe refractory eosinophilic asthma. The observed differences in population subgroups according to plasma eosinophil count, the existence of patients with high levels of immunoglobulin
Manuel David Gil-Sierra, Leticia García-Mochón, Emilio Jesús Alegre-del Rey, Catalina Alarcón de la Lastra-Romero, Marina Sánchez-Hidalgo   +4 more
doaj   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +1 more source

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry

, 2021
BACKGROUND: Oral corticosteroids (OCS) carry serious health risks. Innovative treatment options are required to reduce excessive exposure and promote OCS stewardship.
Gibson, PG, Stevens, S, Katelaris, CH, Lee, J, Katsoulotos, GP, Bowler, S, Kritikos, V, Chung, LP, Grainge, C, Peters, M, Reynolds, PN, Wark, PAB, McDonald, VM, Jenkins, C, Farah, CS, Rimmer, J, Harvey, ES, Thomas, D, Upham, JW, Bowden, JJ, Harrington, J, Radhakrishna, N, Sivakumaran, P, Gillman, A, Chien, J, Langton, D, Baraket, M, Reddel, HK, Hew, M, Bardin, P   +29 more
core   +1 more source

The role of ACT score in mepolizumab discontinuation

, 2023
Mepolizumab is a therapy for severe asthma. We have little knowledge of the characteristics of people in the US that discontinue mepolizumab in clinical care.
Brittany Beck (17695896), Emily Pennington (17695905), Neha Solanki (17695893), Sumita Khatri (12800962), Stephanie King (551654), Kevin Smith (792017), Mark Aronica (747258), Monica Labadia (17695899), Sobia Farooq (17695908), Laura Peterson (10068490), Peng Zhang (2071), Sarah Micklewright (17695902), Serpil Erzurum (337322), Joe Zein (2806369), Suzy Comhair (337321)   +14 more
core   +1 more source

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Allergy, Asthma & Clinical Immunology, 2019
Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the ...
Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro   +7 more
doaj   +1 more source

Chronic Rhinosinusitis and Nasal Polyps in Eosinophilic Granulomatosis With Polyangiitis: A Scoping Review. [PDF]

Int Forum Allergy Rhinol
ABSTRACT Background Chronic rhinosinusitis (CRS) is one of the most common manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), often preceding the diagnosis of systemic vasculitis by several years. The sinonasal presentation of EGPA typically resembles CRS with nasal polyps (CRSwNP), making it clinically indistinguishable from those
Sharma A, Li AY, Kishibe T, Wong D, Sanders KM, Jiang M, Lee H, Song C, Mcintyre K, Pagnoux C, Chan Y, Lee JM, Lee DJ.   +12 more
europepmc   +2 more sources

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice

, 2019
Background: Asthma is an inflammatory disease of the airways with symptoms that vary over time and intensity, sometimes leading to disability or even death. Eosinophilic asthma accounts for 25% of cases of severe asthma.
Olalla Montero-Pérez, Ernesto Sánchez-Gómez, María Beatriz Contreras-Rey   +2 more
core   +1 more source

Эффективность меполизумаба при длительной терапии тяжелой эозинофильной бронхиальной астмы (клинические наблюдения) [PDF]

, 2019
Two clinical cases of severe eosinophilic asthma taking long-term  therapy with mepolizumab  (38 and 45 months are described in the article. Both the cases demonstrate  the effectiveness of the drug both in allergic and non-allergic  (aspirin-induced ...
А. Ф. Иванов, A. F. Ivanov, И. И. Воржева, I. I. Vorzheva, Б. А. Черняк, B. A. Chernyak   +5 more
core   +1 more source